New England Healthcare Executive Network

August 7, 2017, 7:30AM to 10:00AM

7TH ANNUAL SUMMER SOCIAL AND NETWORKING EVENT INCLUDING LIGHTNING PITCHES!

Location:
FOLEY HOAG LLP, Seaport West, 155 Seaport Boulevard, Boston
For Driving and Parking Information, Click Here.

Program Description

Our event of the year that you don\’t want to miss! We are pleased to announce the 7th Annual Summer Social Networking Event Including Lightning Pitches and Keynote Speaker David O\’Dowd from Draper Labs to be held on August 7. (UPDATE: Confirmed presenting companies are listed below.)

This program features a number of snapshot presentations, or lightning pitches, from local pre-venture and early stage Life Science and Medical Device companies. Each pitching company will have 1 minute to impress us with their value proposition and there will also be plenty of opportunity to network with the companies and fellow members.

Please REGISTER today. This is one of our most well-attended events of the year, with health innovation professionals from all backgrounds coming to see what\’s new and exciting in the local biotech, medtech, pharma and health IT economy.

We are at capacity for presenting companies during the lightning pitch segment. If you want to be added to the wait list in the event of cancellation please fill out the brief application formhere.

Keynote Speaker

David O’Dowd, Associate Director in the Biomedical Solutions group, Draper Laboratory

David’s responsibilities are to identify technologies developed at Draper which have potential to address significant clinical unmet needs.

Presentation: Improving Drug Discovery and Manufacturing through Microfluidics

Currently, only 1 in 10 drugs starting clinical trials successfully makes it to market. Once approved, some therapeutics, such a cell therapies, face challenges in efficiently manufacturing a consistent product. In this talk, David will share some of the ways Draper has leveraged its expertise in creating biologically friendly and scalable microfluidic structures to increase the odds of success in drug discovery and bring reliable, cost effective cell therapies to the patient bedside.